department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Docivyx · pharmadog

pharmadog
drugs
Docivyx

drug

patient view →

ML-061

Marketedupdated 2mo ago

by Meridian Laboratories Inc

Approved

community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 11 approved and 71 investigational indications.

indications

investigational

NSCLC

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Docivyx

generic

docetaxel

MOA

Tubulin inhibitor

indication

Adenocarcinoma Of The Gastroesophageal Junction

phase

marketed

Patent cliff

source: FDA Orange Book

first barrier falls

Aug 7, 2031

~5.1 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (18)

May 16, 2036formulationUS 11419842
May 16, 2036formulationUS 12090134
May 16, 2036formulationUS 12090135
Mar 14, 2036formulationUS 10398785
Mar 14, 2036formulationUS 10398785
Mar 14, 2036formulationUS 10398785
Sep 30, 2033formulationUS 8940786
Sep 30, 2033formulationUS 8940786
Sep 30, 2033formulationUS 8940786
Sep 30, 2033formulationUS 9308195
Sep 30, 2033formulationUS 9308195
Sep 30, 2033formulationUS 9308195
Sep 30, 2033method-of-use (U-2562)US 9763880
Sep 30, 2033method-of-use (U-2559)US 9763880
Sep 30, 2033method-of-use (U-2560)US 9763880
Aug 7, 2031formulationUS 10842770
Aug 7, 2031formulationUS 10842770
Aug 7, 2031formulationUS 10842770

Data sources

ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Trials studying ML-061

phase3Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)recruitingn=186
phase2A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumorsrecruitingn=660
phase2A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancercompletedn=12
phase2A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancerrecruitingn=125
phase3Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapyactive not recruitingn=758
phase3Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterationsrecruitingn=400
phase1A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignanciesactive not recruitingn=91
phase2Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancerrecruitingn=152

more trials →